Zevra Therapeutics, Inc. cash flow to debt ratio of -2.53% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Zevra Therapeutics, Inc.'s free cash flow has increased -96.51% from $-69.67M last year to $-2.43M, signaling increasing performance

Zevra Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Zevra Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 1.52 last year to 0.01 today, signaling strengthened financials

Zevra Therapeutics, Inc. has a net debt to EBITDA ratio of 0.01x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Zevra Therapeutics, Inc.'s interest coverage ratio is -6.32, which means that the company struggles to meet interest obligations, signaling financial risk.

Zevra Therapeutics, Inc.'s profit margin has increased (-122.73%) in the last year from -446.85% to 101.58%, signaling increasing performance

Zevra Therapeutics, Inc.'s short-term assets of $223.01M exceed its short-term liabilities of $39.28M

Zevra Therapeutics, Inc.'s return on assets of 44.59% is higher than the 5.00% threshold, indicating efficient asset utilization

Zevra Therapeutics, Inc.'s return on equity of 81.34%, is higher than 15.00%, indicating good performance

Zevra Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Zevra Therapeutics, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Zevra Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Zevra Therapeutics, Inc. has negative free cash flow, indicating cash burn

Zevra Therapeutics, Inc.'s yearly earnings has increased -178.88% since last year from $-105.51M to $83.23M, signaling increasing performance

Zevra Therapeutics, Inc.'s yearly revenue has increased 350.91% since last year from $23.61M to $106.47M, signaling increasing performance

ROIC -19.57% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Zevra Therapeutics, Inc.'s 3-year revenue CAGR of 118.82% is positive, indicating growing revenue over the past 3 years

Zevra Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Zevra Therapeutics, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Zevra Therapeutics, Inc. has insufficient data to evaluate this check.

Zevra Therapeutics, Inc. has an earnings yield of 16.28%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Zevra Therapeutics, Inc. is overvalued relative to its fair value price of 11.76 based on EBITDA multiple model

Zevra Therapeutics, Inc. has an EV/EBITDA ratio of 7.83x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Zevra Therapeutics, Inc. is overvalued relative to its fair value price of -65.01 based on Earnings Fair Value model

Zevra Therapeutics, Inc. has a PEG-ratio under 1 which is considered undervalued

Zevra Therapeutics, Inc. has a price-to-book ratio of 3.71x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Zevra Therapeutics, Inc. has a price-to-sales ratio of 6.24x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue